Benoît Baron

3.0k total citations · 1 hit paper
24 papers, 2.1k citations indexed

About

Benoît Baron is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Benoît Baron has authored 24 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 10 papers in Radiology, Nuclear Medicine and Imaging and 7 papers in Oncology. Recurrent topics in Benoît Baron's work include Prostate Cancer Treatment and Research (14 papers), Radiopharmaceutical Chemistry and Applications (9 papers) and Hormonal and reproductive studies (6 papers). Benoît Baron is often cited by papers focused on Prostate Cancer Treatment and Research (14 papers), Radiopharmaceutical Chemistry and Applications (9 papers) and Hormonal and reproductive studies (6 papers). Benoît Baron collaborates with scholars based in France, United States and Belgium. Benoît Baron's co-authors include Françis Lévi, Neal D. Shore, Arnauld Villers, Brad Rosbrook, Arnulf Stenzl, Taro Iguchi, Andrew J. Armstrong, Jennifer Sugg, Daniel P. Petrylak and Lucy Chen and has published in prestigious journals such as Journal of Clinical Oncology, Advanced Drug Delivery Reviews and Clinical Cancer Research.

In The Last Decade

Benoît Baron

23 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

2019 686 citations Andrew J. Armstrong, Russell Z. Szmulewitz et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Benoît Baron France	16	1.4k	696	350	343	290	24	2.1k
Joo Ern Ang United Kingdom	17	391 0.3×	872 1.3×	403 1.2×	117 0.3×	213 0.7×	50	2.0k
Marina Elena Cazzaniga Italy	28	639 0.5×	2.1k 3.0×	609 1.7×	99 0.3×	245 0.8×	138	3.2k
G Gardani Italy	20	499 0.4×	660 0.9×	163 0.5×	286 0.8×	136 0.5×	67	1.7k
P. Escudero Spain	23	792 0.6×	1.7k 2.4×	186 0.5×	62 0.2×	195 0.7×	92	2.7k
Marco Tampellini Italy	25	576 0.4×	1.1k 1.6×	237 0.7×	252 0.7×	546 1.9×	91	2.2k
Jean-Louis Misset France	22	513 0.4×	1.6k 2.4×	301 0.9×	185 0.5×	301 1.0×	42	2.5k
Manuel Benavides Spain	26	603 0.4×	1.6k 2.3×	445 1.3×	70 0.2×	168 0.6×	94	2.5k
Mirosław Kozłowski Poland	23	626 0.4×	661 0.9×	581 1.7×	107 0.3×	54 0.2×	83	1.9k
Xiaohong R. Yang United States	28	555 0.4×	1.2k 1.7×	866 2.5×	175 0.5×	92 0.3×	106	2.7k
Richard D. Kim United States	29	797 0.6×	1.7k 2.4×	653 1.9×	160 0.5×	59 0.2×	198	3.6k

Countries citing papers authored by Benoît Baron

Since Specialization

Citations

This map shows the geographic impact of Benoît Baron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benoît Baron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benoît Baron more than expected).

Fields of papers citing papers by Benoît Baron

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benoît Baron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benoît Baron. The network helps show where Benoît Baron may publish in the future.

Co-authorship network of co-authors of Benoît Baron

This figure shows the co-authorship network connecting the top 25 collaborators of Benoît Baron. A scholar is included among the top collaborators of Benoît Baron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benoît Baron. Benoît Baron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Robinson, Cynthia, Benoît Baron, D. Lowson, et al.. (2025). Safety, immunogenicity and pregnancy outcomes in mothers and infants after vaccination with an adenovirus-vector COVID-19 vaccine during pregnancy. Human Vaccines & Immunotherapeutics. 21(1). 2538340–2538340. 1 indexed citations

Iguchi, Taro, Go Kimura, Satoshi Fukasawa, et al.. (2021). Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone‐sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study. International Journal of Urology. 28(7). 765–773. 15 indexed citations

Payne, Heather, Angus Robinson, Serena Hilman, et al.. (2021). A European, prospective, observational study of enzalutamide in patients with metastatic castration‐resistant prostate cancer: PREMISE. International Journal of Cancer. 150(5). 837–846. 13 indexed citations

Armstrong, Andrew J., Russell Z. Szmulewitz, Daniel P. Petrylak, et al.. (2019). Phase III study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial.. Journal of Clinical Oncology. 37(7_suppl). 687–687. 15 indexed citations

Armstrong, Andrew J., Russell Z. Szmulewitz, Daniel P. Petrylak, et al.. (2019). ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC).. Journal of Clinical Oncology. 37(15_suppl). 5048–5048. 4 indexed citations

Armstrong, Andrew J., Russell Z. Szmulewitz, Daniel P. Petrylak, et al.. (2019). ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. Journal of Clinical Oncology. 37(32). 2974–2986. 686 indexed citations breakdown →

Lam, Elaine T., Russell Z. Szmulewitz, Leonard J. Appleman, et al.. (2018). Safety of continued administration of enzalutamide in patients with prostate cancer who showed benefit from prior exposure: A phase 2 open-label extension study.. Journal of Clinical Oncology. 36(6_suppl). 303–303.

Bono, Johann S. de, Simon Chowdhury, Susan Feyerabend, et al.. (2017). Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe. European Urology. 74(1). 37–45. 80 indexed citations

Siemens, D. Robert, Laurence Klotz, Axel Heidenreich, et al.. (2017). Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial. The Journal of Urology. 199(1). 147–154. 29 indexed citations

10.

Bono, Johann S. de, Simon Chowdhury, Susan Feyerabend, et al.. (2017). Efficacy and safety of enzalutamide (ENZA) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate (Abi): A multicenter, single-arm, open-label study.. Journal of Clinical Oncology. 35(6_suppl). 165–165. 2 indexed citations

11.

Heidenreich, Axel, Simon Chowdhury, Laurence Klotz, et al.. (2016). Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial. European Urology. 71(4). 534–542. 28 indexed citations

12.

Tombal, Bertrand, Michael Borre, Per Rathenborg, et al.. (2015). Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results. European Urology. 68(5). 787–794. 34 indexed citations

13.

Shore, Neal D., Axel Heidenreich, Arnauld Villers, et al.. (2015). PII-LBA4 TERRAIN TRIAL: PROSTATE-SPECIFIC ANTIGEN KINETICS AND QUALITY OF LIFE RESULTS OF ENZALUTAMIDE VERSUS BICALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. The Journal of Urology. 193(4S). 2 indexed citations

14.

Loriot, Yohann, Karim Fizazi, Robert J. Jones, et al.. (2014). Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. Investigational New Drugs. 32(5). 995–1004. 54 indexed citations

15.

Coudert, Bruno, Christian Focan, Dominique Genet, et al.. (2008). A Randomized Multicenter Study of Optimal Circadian Time of Vinorelbine Combined with Chronomodulated 5‐Fluorouracil in Pretreated Metastatic Breast Cancer Patients: EORTC Trial 05971. Chronobiology International. 25(5). 680–696. 20 indexed citations

16.

Lévi, Françis, C. Focan, Abdoulaye Karaboué, et al.. (2007). Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Advanced Drug Delivery Reviews. 59(9-10). 1015–1035. 149 indexed citations

17.

Paolettí, Xavier, Benoît Baron, Patrick Schöffski, et al.. (2006). Using the continual reassessment method: Lessons Learned from an EORTC phase I dose finding study. European Journal of Cancer. 42(10). 1362–1368. 21 indexed citations

18.

Giacchetti, Sylvie, Georg A. Bjarnason, Carlo Garufi, et al.. (2006). Phase III Trial Comparing 4-Day Chronomodulated Therapy Versus 2-Day Conventional Delivery of Fluorouracil, Leucovorin, and Oxaliplatin As First-Line Chemotherapy of Metastatic Colorectal Cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group. Journal of Clinical Oncology. 24(22). 3562–3569. 178 indexed citations

19.

Neymark, Niels, et al.. (2002). Cost Effectiveness of Paclitaxel/Cisplatin Compared with Cyclophosphamide/Cisplatin in the Treatment of Advanced Ovarian Cancer in Belgium. PharmacoEconomics. 20(7). 485–497. 18 indexed citations

20.

Baron, Benoît, et al.. (2001). Chronomodulation: optimal time finding design. Controlled Clinical Trials. 22. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact